Dana Hilt
Dr. Dana C. Hilt, MD is the CMO of Progentos Therapeutics with more than 25 years of drug development experience, primarily of Central Nervous System (CNS) drugs. Dr. Hilt has extensive experience in Phases 1 to 4 development of drugs for conditions including Alzheimer’s disease, depression, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, schizophrenia, and other non-CNS conditions including CNS malignancies.
Dr. Hilt was most recently the Chief Medical Officer at Frequency Therapeutics and led the design of the remyelination clinical development program acquired by Progentos. Dr. Hilt has held senior development and management positions as Chief Medical Officer at several pharmaceutical companies, including Lysosomal Therapeutics, Guilford Pharmaceuticals, Ascend Pharmaceuticals, and Critical Therapeutics. Prior to that, Dr. Hilt worked with Amgen, establishing a Clinical Neuroscience Group that focused on the potential therapeutic applications of neurotrophic factors in degenerative neurologic diseases such as Parkinson’s disease.
Dr. Hilt gained his medical degree from Tufts University School of Medicine in Boston and trained in Internal Medicine at Harvard Medical School and Neurology at the Johns Hopkins Hospital. He has held academic Neurology positions at the University of Maryland and University of Southern California where he conducted molecular biological research, taught clinical Neurology and basic neurobiology, and cared for patients with neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and ALS.
